BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 34370654)

  • 1. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
    Gaudio A; Xourafa A; Rapisarda R; Castellino P
    Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis management in patients with breast cancer: EMAS position statement.
    Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
    Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
    Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
    Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidance for the management of aromatase inhibitor-associated bone loss.
    Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
    Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.
    Tremblay D; Patel V; Fifer KM; Caro J; Kolodka O; Mandelli J; Shapiro CL
    Support Care Cancer; 2018 Jan; 26(1):197-202. PubMed ID: 28744736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
    Chukir T; Liu Y; Farooki A
    Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.
    Bassatne A; Bou Khalil A; Chakhtoura M; Arabi A; Van Poznak C; El-Hajj Fuleihan G
    Metabolism; 2022 Mar; 128():154962. PubMed ID: 34958816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors.
    Rachner TD; Göbel A; Jaschke NP; Hofbauer LC
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32674135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
    Hadji P; Aapro MS; Body JJ; Bundred NJ; Brufsky A; Coleman RE; Gnant M; Guise T; Lipton A
    Ann Oncol; 2011 Dec; 22(12):2546-2555. PubMed ID: 21415233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing Bone Health in Breast Cancer.
    Kearns AE
    Endocr Pract; 2023 May; 29(5):408-413. PubMed ID: 36509360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.